Valuation: Nykode Therapeutics

Market Cap 1.05B 106M 92.91M 85.65M 80.18M 150M 10B 153M 1.03B 398M 4.94B 398M 389M 17.13B P/E 2026 *
-4.98x
P/E 2027 * -34.8x
Enterprise Value 566M 57.08M 50.05M 46.13M 43.19M 80.99M 5.38B 82.67M 554M 215M 2.66B 214M 210M 9.23B EV / Sales 2026 *
-
EV / Sales 2027 * 2.93x
Free-Float
56.4%
Yield 2026 *
-
Yield 2027 * -
1 day+0.78%
1 week+0.78%
Current month+3.51%
1 month-3.42%
3 months+5.22%
6 months+38.91%
Current year+34.54%
1 week 3.14
Extreme 3.145
3.29
1 month 2.97
Extreme 2.97
3.6
Current year 2.21
Extreme 2.21
4.1
1 year 1.44
Extreme 1.44
4.1
3 years 1.44
Extreme 1.44
30.18
5 years 1.44
Extreme 1.44
85.3
10 years 1.44
Extreme 1.44
93
Manager TitleAgeSince
Chief Executive Officer 54 01/01/2019
President 49 01/01/2017
Director of Finance/CFO 51 03/05/2021
Director TitleAgeSince
Director/Board Member 54 -
Director/Board Member 57 -
Chairman 45 23/04/2025
Date Insider Type Main position Quantity % Market Cap.
27/03/25BuyCompany 3,000,000 0.9187%
20/12/24Sell

Director

100,000 0.0306%
20/12/24Buy

Director

100,000 0.0306%
Change 5-day change 1-year change 3-year change Capi.($)
+0.78%+0.78%+72.61%-87.62% 107M
+0.33%+1.37%+64.03%+119.11% 55.35B
+0.82%+15.05%+74.28%+86.70% 51.92B
-0.97%-1.15%-16.01%-16.63% 22.76B
+1.01%+7.00%+3.71%+429.93% 22.64B
-0.18%+7.20%+28.56%-12.48% 17.36B
-1.10%+4.00%+28.70%-34.51% 16.1B
-3.35%+8.96%+135.18%+294.38% 13.96B
+2.19%+5.90%+26.20%+179.45% 13.38B
+1.31%+0.53%+27.21% - 12.27B
Average +0.08%+4.38%+44.45%+106.48% 22.58B
Weighted average by Cap. +0.17%+5.29%+47.19%+122.58%

Financials

2026 *2027 *
Net sales - 162M 16.3M 14.29M 13.17M 12.33M 23.12M 1.54B 23.6M 158M 61.26M 760M 61.19M 59.86M 2.63B
Net income -208M -20.95M -18.37M -16.93M -15.85M -29.73M -1.98B -30.35M -204M -78.76M -977M -78.68M -76.96M -3.39B -41.58M -4.19M -3.67M -3.39M -3.17M -5.95M -395M -6.07M -40.71M -15.75M -195M -15.74M -15.39M -677M
Net Debt -485M -48.89M -42.87M -39.51M -36.99M -69.37M -4.61B -70.81M -475M -184M -2.28B -184M -180M -7.9B -578M -58.2M -51.03M -47.04M -44.04M -82.58M -5.49B -84.29M -565M -219M -2.71B -219M -214M -9.41B
Logo Nykode Therapeutics
Nykode Therapeutics ASA is a Norway-based clinical-stage biopharmaceutical platform company dedicated to the discovery and development of vaccines and immunotherapies for cancer and infectious diseases. Nykode uses its vaccine technology platform to generate therapeutics in disease indications with unmet medical need. The Company develops next generation vaccines for clinical use, based on a deep understanding of immunological principles. Nykode Therapeutics’ main product candidates are VB10.16 and VB10.NEO. VB10.16 is a therapeutic cancer vaccine against HPV16-related cancers. VB10. NEO is a therapeutic cancer neoantigen vaccine. The Company also has two universal COVID-19 vaccine candidates in development.
Employees
57
Date Price Change Volume
26/06/26 NOK 3.245 +0.78% 196,195
25/06/26 NOK 3.220 -0.16% 124,490
24/06/26 NOK 3.225 -0.62% 417,905
23/06/26 NOK 3.245 0.00% 472,865
22/06/26 NOK 3.245 +0.78% 345,815
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
3.220NOK
Average target price
5.000NOK
Spread / Average Target
+55.28%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VACC Stock